Interleukin‑18 and ‑10 may be associated with lymph node metastasis in breast cancer

Ma, Teng; Kong, Meng

doi:10.3892/ol.2021.12515

Cited by 7 publications

(6 citation statements)

References 37 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, IL-18 expression was closely correlated with lymphovascular invasion (LVI) and lymph node metastasis. In fact, previous studies have demonstrated a significant increase in the expression of IL-18 in other tumor types, such as gastric cancer, breast cancer, lung cancer, and renal cell carcinoma [12][13][14]22]. Furthermore, tumor-derived IL-18 displays an important role in triggering the metastasis of those cancers by increasing angiogenesis, facilitating immune escape, and decreasing intercellular adhesion [23][24][25][26].…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, however, some studies indicate that IL-18 exhibits procancer effects. IL-18 levels are significantly increased a series of neoplasms, such as esophageal, pancreatic, and prostate cancer, and associated with advanced tumor stage and poor prognosis [12][13][14]. Thus, IL-18 is considered to have a double-edged regulatory effect on tumor behavior, which may depend on the neoplastic milieu and/or tumor types.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Levels of Interleukin-18 are Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Chun,

Lu,

Chen

et al. 2024

Horm Metab Res

View full text Add to dashboard Cite

Interleukin-18 (IL-18) is a proinflammatory cytokine that primarily stimulates the Th1 immune response. IL-18 exhibits anticancer activity and has been evaluated in clinical trials as a potential cancer treatment. However, evidence suggests that it may also facilitate the development and progression of some cancers. So far, the impact of IL-18 on papillary thyroid cancer (PTC) has not been investigated. In this study, we found that the expression of IL-18 was significantly increased in PTC compared to normal thyroid tissue. Elevated IL-18 expression was closely associated with lymphovascular invasion and lymph node metastases. Furthermore, compared to PTC patients with no nodal metastasis, serum IL-18 levels were slightly increased in patients with 1–4 nodal metastases and significantly elevated in patients with 5 or more nodal metastases. The pro-metastatic effect of IL-18 may be attributed to the simultaneous increase in the expression of S100A10, a known factor that is linked to nodal metastasis in PTC. In addition, the activation of several pathways, such as the intestinal immune network for lgA production and Staphylococcus aureus infection, may be involved in the metastasis process. Taken together, IL-18 may trigger pro-metastatic activity in PTC. Therefore, suppressing the function of IL-18 rather than enhancing it appears to be a reasonable strategy for treating aggressive PTC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Elevated Levels of Interleukin-18 are Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Chun,

Lu,

Chen

et al. 2024

Horm Metab Res

View full text Add to dashboard Cite

show abstract

“…IL-18 modulates Th1 and Th2 immune responses, as well as the activation of NK cells and macrophages[ 39 ]. It is reported that the IL-18 protein is strongly expressed in human BC and lymph node tissues, and is directly associated with lymph node metastasis in BC[ 40 ]. MYD88 serves a critical function in both innate and adaptive immune responses.…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

Wu,

Wei,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Breast cancer (BC), a leading malignant disease, affects women all over the world. Cancer associated fibroblasts (CAFs) stimulate epithelial-mesenchymal transition, and induce chemoresistance and immunosuppression. AIM To establish a CAFs-associated prognostic signature to improve BC patient outcome estimation. METHODS We retrieved the transcript profile and clinical data of 1072 BC samples from The Cancer Genome Atlas (TCGA) databases, and 3661 BC samples from the The Gene Expression Omnibus. CAFs and immune cell infiltrations were quantified using CIBERSORT algorithm. CAF-associated gene identification was done by weighted gene co-expression network analysis. A CAF risk signature was established via univariate, least absolute shrinkage and selection operator regression, and multivariate Cox regression analyses. The receiver operating characteristic (ROC) and Kaplan-Meier curves were employed to evaluate the predictability of the model. Subsequently, a nomogram was developed with the risk score and patient clinical signature. Using Spearman's correlations analysis, the relationship between CAF risk score and gene set enrichment scores were examined. Patient samples were collected to validate gene expression by quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS Employing an 8-gene (IL18, MYD88, GLIPR1, TNN, BHLHE41, DNAJB5, FKBP14, and XG) signature, we attempted to estimate BC patient prognosis. Based on our analysis, high-risk patients exhibited worse outcomes than low-risk patients. Multivariate analysis revealed the risk score as an independent indicator of BC patient prognosis. ROC analysis exhibited satisfactory nomogram predictability. The area under the curve showed 0.805 at 3 years, and 0.801 at 5 years in the TCGA cohort. We also demonstrated that a reduced CAF risk score was strongly associated with enhanced chemotherapeutic outcomes. CAF risk score was significantly correlated with most hallmark gene sets. Finally, the prognostic signature were further validated by qRT-PCR. CONCLUSION We introduced a newly-discovered CAFs-associated gene signature, which can be employed to estimate BC patient outcomes conveniently and accurately.

show abstract

“…IL-18 modulates Th1 and Th2 immune responses, as well as the activation of NK cells and macrophages [33]. It is reported that the IL-18 protein is strongly expressed in human BC and lymph node tissues, and is directly associated with lymph node metastasis in BC [34]. MYD88 serves a critical function in both innate and adaptive immune responses.…”

Section: Discussionmentioning

confidence: 99%

A new prognostic signature based on cancer associated fibroblast-driven genes in breast cancer

Wei

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Breast cancer, a leading malignant disease, affects women all over the world. Cancer associated fibroblasts (CAFs) stimulate epithelial-mesenchymal transition, and induce chemoresistance and immunosuppression. Objective This study aims to establish a CAFs-associated prognostic signature to improve BC patient outcome estimation. Methods We retrieved the transcript profile and clinical data of 1072 BC samples from TCGA databases, and 3661 BC samples from the GEO. CAFs and immune cell infiltrations were quantified using CIBERSORT algorithm. CAF-associated gene identification was done by WGCNA. A CAF risk signature was established via univariate, LASSO regression, and multivariate Cox regression analyses. The receiver operating characteristic (ROC) and Kaplan-Meier curves were employed to evaluate the predictability of the model. Subsequently, a nomogram was developed with the risk score and patient clinical signature. Using Spearman's correlations analysis, the relationship between CAF risk score and gene set enrichment scores were examined. Results Employing an 8-gene (IL18, MYD88, GLIPR1, TNN, BHLHE41, DNAJB5, FKBP14, and XG) signature, we attempted to estimate BC patient prognosis. Based on our analysis, high-risk patients exhibited worse outcomes than low-risk patients. Multivariate analysis revealed the risk score as an independent indicator of BC patient prognosis. ROC analysis exhibited satisfactory nomogram predictability. The AUC showed 0.805 at 3 years, and 0.801 at 5 years in the TCGA cohort. We also demonstrated that a reduced CAF risk score was strongly associated with enhanced chemotherapeutic outcomes. CAF risk score was significantly correlated with most hallmark gene sets. Conclusion We introduced a newly-discovered CAFs-linked gene signature, which served as an independent marker of BC patient prognosis.

show abstract

Interleukin‑18 and ‑10 may be associated with lymph node metastasis in breast cancer

Cited by 7 publications

References 37 publications

Elevated Levels of Interleukin-18 are Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Elevated Levels of Interleukin-18 are Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

A new prognostic signature based on cancer associated fibroblast-driven genes in breast cancer

Contact Info

Product

Resources

About